Accountable care organizations all over the country have shown that no single method can work for every system, said Risa Lavizzo-Mourey, MD, MBA, outgoing president and CEO of the Robert Wood Johnson Foundation.
Accountable care organizations all over the country have shown that no single method can work for every system, said Risa Lavizzo-Mourey, MD, MBA, outgoing president and CEO of the Robert Wood Johnson Foundation.
Transcript (slightly modified)
After watching ACOs for more than 5 years, what has the Robert Wood Johnson Foundation learned about how these new delivery models benefit healthcare quality and value?
Well, over the last few years as many observers have watched accountable care organizations grow and evolve, I think there are a few things that are pretty clear. The first is that there’s no one method that’s going to work. There’s a lot of different approaches that are being tried in different regions, and with great effect. For example, in Oregon, they’ve taken an approach of really basing it in a home care model and looking at how organizations can coordinate care.
In another part of the country, in the Midwest, in Minneapolis and Hennepin County, they’ve been able to show that by doing a risk assessment and understanding the social and economic needs of their patient population, they could add to the traditional healthcare services those resources that patients need. So for example if a person needs housing, they can bring that in, in a way that actually ensures that all of the needs, not just those that are typically delivered within the healthcare system, are met, and patients can stay healthier.
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
August 1st 2025Prenatal exposure to per- and polyfluoroalkyl substances (PFAS), a class of persistent environmental pollutants, was linked to significant shifts in infant T helper cell development, raising concerns about long-term effects on vaccine response, immune regulation, and disease susceptibility.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More